XML 14 R4.htm IDEA: XBRL DOCUMENT v3.23.3
Condensed Consolidated Statements of Operations (Unaudited) - USD ($)
 3 Months Ended 9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Operating expenses:        
Research and development $ 10,454,072 $ 30,529,108 $ 40,055,287 $ 86,454,632
General and administrative 12,238,566 8,208,053 36,817,686 36,092,024
Total operating expenses 22,692,638 38,737,161 76,872,973 122,546,656
Loss from operations (22,692,638) (38,737,161) (76,872,973) (122,546,656)
Other (expenses) income:        
Gain on settlement of fees 6,351,606
Interest/investment income, net 1,321,441 827,614 3,892,478 1,544,898
Realized loss on short-term investments (51,714) (561,648) (718,422) (552,171)
Unrealized (loss) gain on short-term investments (579,147) (947,512) 72,329 (3,897,135)
Total other (expense) income – net 690,580 (681,546) 3,246,385 3,447,198
Net loss $ (22,002,058) $ (39,418,707) $ (73,626,588) $ (119,099,458)
Loss per common share – basic and diluted (in Dollars per share) $ (0.73) $ (1.31) $ (2.45) $ (4.04)
Weighted average number of common shares outstanding – basic and diluted (in Shares) 30,099,203 30,063,735 30,099,203 29,470,198